KATIE FEE: Open Payments
NPI 1407443658 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,050 in 49 payments from 17 companies in 2025. Trend: 2023 $943 · 2024 $773 · 2025 $1,050
Food & beverage: $1,050
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $294 |
| Lilly USA, LLC | 8 | $129 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $124 |
| Astellas Pharma US Inc | 4 | $81 |
| ABBVIE INC. | 3 | $62 |
| GlaxoSmithKline, LLC. | 2 | $60 |
| Amgen Inc. | 4 | $60 |
| Novo Nordisk Inc | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Medtronic, Inc. | 1 | $27 |
Products named: BREZTRI, XIFAXAN, FARXIGA, Veozah, TRELEGY ELLIPTA, MOUNJARO, OTEZLA, QULIPTA.
Industry payments across KS — which companies pay providers there.
